Genelux’s (GNLX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Genelux (NASDAQ:GNLX) in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $30.00 price target on the stock.

Genelux Stock Down 12.6 %

Shares of Genelux stock opened at $3.40 on Tuesday. The stock has a market capitalization of $117.43 million, a price-to-earnings ratio of -3.58 and a beta of -1.41. Genelux has a twelve month low of $1.60 and a twelve month high of $6.50. The company has a 50-day simple moving average of $4.02 and a two-hundred day simple moving average of $3.09.

Institutional Investors Weigh In On Genelux

Institutional investors have recently made changes to their positions in the stock. Apollon Wealth Management LLC raised its holdings in Genelux by 20.4% in the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after acquiring an additional 2,857 shares in the last quarter. LifeSteps Financial Inc. grew its holdings in shares of Genelux by 11.1% during the 4th quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock worth $205,000 after purchasing an additional 8,715 shares in the last quarter. Brown Brothers Harriman & Co. increased its position in shares of Genelux by 76.2% in the third quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company’s stock worth $50,000 after purchasing an additional 9,114 shares during the period. Virtu Financial LLC acquired a new position in Genelux in the fourth quarter valued at about $25,000. Finally, Raymond James Financial Inc. acquired a new position in Genelux in the fourth quarter valued at about $41,000. 37.33% of the stock is currently owned by institutional investors.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.